Ivonescimab HARMONi-2 shows OS benefit: HR 0.73, median OS 30.8 vs 22.6 months vs pembrolizumab

Summit Therapeutics Inc.

HARMONi-2 OS HR 0.73 (95% CI 0.57-0.95; p=0.009); median OS 30.8 vs 22.6 months.
PD-L1 high subgroup HR 0.58; PD-L1 low HR 0.85; squamous HR 0.65; non-squamous HR 0.79.
Serious TRAEs: 29.9% (ivonescimab) vs 21.6% (pembrolizumab); discontinuation 4.1% vs 5.0%.
Summit's global Phase III HARMONi-7 (NCT06767514) targets 780 patients with PD-L1 high-expressing NSCLC.

Featured in Daily 8-K Digest

Selected #9 for 2026-09-14. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.